Focused Alpha LLC’s Corcept Therapeutics CORT Stock Holding History

Focused Alpha LLC’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,421	Closed	-$1.31M	–	274
2026 Q1	$1.31M	Buy	+32,421	New	+$1.21M	0.4%	47

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focused Alpha LLC's CORT Position: Q2 2026 in Review

Focused Alpha LLC sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 32,421 shares — an estimated $1.31M sold.

Focused Alpha LLC first reported a position in CORT in Q1 2026 and held it in 1 quarter. The position peaked at $1.31M in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Focused Alpha LLC reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
Focused Alpha LLC sold 32,421 Corcept Therapeutics shares in Q2 2026, an estimated $1.31M.
Focused Alpha LLC first reported a position in Corcept Therapeutics in Q1 2026 and held it in 1 quarter.
Focused Alpha LLC's Corcept Therapeutics position peaked at $1.31M in Q1 2026.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Focused Alpha LLC's 13F filing for Q2 2026, filed 7 Aug 2026.